Monitor for completion of due diligence on the PanOmics acquisition and shareholder approval of the equity issuance. Watch for potential dilution from convertible debt conversions and warrant exercises. The acquisition could provide near-term revenue from diagnostics but carries integration risks.
Price Chart
Executive Summary
Profusa amended its securities purchase agreement to allow for up to $12.2 million in additional convertible debt financing, issued a $555,600 convertible note to Ascent Partners, and entered a non-binding $30 million letter of intent to acquire Bio Insights' PanOmics diagnostics assets. The deal includes equity issuance, royalties, and board representation, subject to due diligence and shareholder approval.
Key Financial Metrics
Key Facts
- Amended securities purchase agreement to allow up to $12,222,222 in additional convertible notes
- Issued $555,555.55 convertible promissory note to Ascent Partners Fund LLC with 12% interest and $0.50 conversion price
- Issued warrant to purchase 1,111,111 shares at $0.50 per share as consideration for amendment
- Entered non-binding letter of intent to acquire Bio Insights' PanOmics assets for $30 million in equity
- Acquisition consideration includes 460,000 common shares and preferred stock convertible to 59,540,000 common shares
- Bio Insights to receive 3% royalty on net revenue and right to nominate one board member
- Transaction subject to shareholder approval, due diligence, and other customary closing conditions
Financial Impact
Potential $30 million equity dilution from acquisition and up to $12.2 million in convertible debt financing
Risk Factors
- Acquisition may not close due to due diligence issues or failure to obtain shareholder approval
- Convertible debt and warrant issuance could lead to significant shareholder dilution
- Integration of PanOmics platform may be challenging and fail to deliver expected synergies
- The company may face difficulties raising the planned $10 million financing to support the acquisition
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-040111 |
| Document: ea028515101ex10-2.htm | 0001213900-26-040111 |
| Document: ea0285151-8k_profusa.htm | 0001213900-26-040111 |
| Document: ea028515101ex99-1.htm | 0001213900-26-040111 |
| Document: ea028515101ex99-2.htm | 0001213900-26-040111 |
| Document: 0001213900-26-040111-index-headers.html | 0001213900-26-040111 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 8, 2026 20w ago | 8-K | — | awaiting T+20 | — | — |
May 26, 2026 21w ago | 8-K | — | awaiting T+20 | — | — |
May 15, 2026 23w ago | 8-K | — | awaiting T+20 | — | — |
May 8, 2026 24w ago | 8-K | — | awaiting T+20 | — | — |
May 1, 2026 25w ago | S-1/A | — | awaiting T+20 | — | — |
Apr 29, 2026 25w ago | 8-K | — | awaiting T+20 | — | — |
Apr 28, 2026 25w ago | S-1 | — | awaiting T+20 | — | — |
Apr 27, 2026 26w ago | 8-K | — | awaiting T+20 | — | — |
Apr 24, 2026 26w ago | 8-K | — | awaiting T+20 | — | — |
Apr 6, 2026 29w ago | 8-K | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers